TW200510367A - Novel lapachone compounds, their preparation, and the use thereof - Google Patents

Novel lapachone compounds, their preparation, and the use thereof

Info

Publication number
TW200510367A
TW200510367A TW092132328A TW92132328A TW200510367A TW 200510367 A TW200510367 A TW 200510367A TW 092132328 A TW092132328 A TW 092132328A TW 92132328 A TW92132328 A TW 92132328A TW 200510367 A TW200510367 A TW 200510367A
Authority
TW
Taiwan
Prior art keywords
preparation
compounds
lapachone compounds
novel
prevention
Prior art date
Application number
TW092132328A
Other languages
English (en)
Chinese (zh)
Inventor
zhi-wei Jiang
Dasharatha Reddy
Samuel K Ackerman
June Salvesen
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of TW200510367A publication Critical patent/TW200510367A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW092132328A 2002-11-18 2003-11-18 Novel lapachone compounds, their preparation, and the use thereof TW200510367A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
TW200510367A true TW200510367A (en) 2005-03-16

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092132328A TW200510367A (en) 2002-11-18 2003-11-18 Novel lapachone compounds, their preparation, and the use thereof

Country Status (12)

Country Link
US (1) US20040266857A1 (enExample)
EP (1) EP1567515A4 (enExample)
JP (1) JP2006508147A (enExample)
CN (1) CN1729183A (enExample)
AR (1) AR056613A1 (enExample)
AU (1) AU2003295738A1 (enExample)
BR (1) BR0316296A (enExample)
CA (1) CA2506340A1 (enExample)
EA (1) EA200500849A1 (enExample)
MX (1) MXPA05005314A (enExample)
TW (1) TW200510367A (enExample)
WO (1) WO2004045557A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361691B2 (en) 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
WO2005053682A2 (en) 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2005082355A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2556794A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
CA2555950A1 (en) 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
CA2556823A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
JP2007523191A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 血液腫瘍の治療のためのβ−ラパコンの使用
WO2006020719A2 (en) 2004-08-11 2006-02-23 Arqule, Inc. Aminoacid conjugates of beta - lapachone for tumor targeting
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006078503A2 (en) 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
JP2009538298A (ja) * 2006-05-26 2009-11-05 アークル インコーポレイテッド 新規のラパコン化合物およびその使用方法
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
EP2137168B1 (en) * 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
BRPI0810717A2 (pt) 2007-04-30 2016-05-24 Arqule Inc sulfonato hidroxi de composto de quinona e seus usos
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
SG186129A1 (en) * 2010-06-01 2013-01-30 Belle Aire Fragrances Inc Oral odor control method and product
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) * 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US20040209942A1 (en) * 2002-07-17 2004-10-21 Li Chiang J. Activated checkpoint therapy and methods of use thereof
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.

Also Published As

Publication number Publication date
AR056613A1 (es) 2007-10-17
MXPA05005314A (es) 2005-10-19
EP1567515A2 (en) 2005-08-31
JP2006508147A (ja) 2006-03-09
WO2004045557A3 (en) 2004-08-12
EP1567515A4 (en) 2008-04-23
WO2004045557A2 (en) 2004-06-03
CN1729183A (zh) 2006-02-01
BR0316296A (pt) 2005-12-13
AU2003295738A1 (en) 2004-06-15
US20040266857A1 (en) 2004-12-30
EA200500849A1 (ru) 2006-02-24
CA2506340A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
IL260127B (en) mek inhibitors and methods of using them
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
AU2004263179A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
TW200510416A (en) P38 inhibitors and methods of use thereof
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
GB0112348D0 (en) Compounds
WO2006034154A3 (en) Salts of 5-azacytidine
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
WO2004026253A3 (en) Novel lapacho compounds and methods of use thereof
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
PL1809288T3 (pl) Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.
AUPS234402A0 (en) Anti-tumour polycyclic carboxamides
TW200504051A (en) Novel acridine derivatives and their use as medicaments